Of those, roughly 1 in 5 had an active GLP-1 prescription
We offer a special 3-month trial program for $297
Post-Meal Walks: Once you finish eating, go for an easy walk, ideally outside in the fresh air
Speed and Onboarding If you want medication in your hand this week, one of these providers can make that happen
Carol Wysham reported on 978 patients with type 2 diabetes in the 52-week, phase III AWARD-1 trial who were randomized to dulaglutide at 1.5 or 0.75 mg, the injectable GLP-1 agonist exenatide at 10 mcg twice daily, or placebo
You get 24/7 unlimited messaging with licensed providers at no additional cost for follow-ups, dose adjustments, or questions about side effects